Two of these patients showed objective responses with a tendency to convert an immune-cold into an immunoactive biomarker on tumor biopsies, and another early targeting strategy for LAG-3 involved the bispecific monoclonal antibody tebotelimab (MGD013), which cotargeted LAG-3 and PD-1 [82–84]. Here, PDCD1 is linked to neoplasm.